logo
#

Latest news with #PEKK

Hexcel unveils breakthrough thermoplastic component at Paris air show
Hexcel unveils breakthrough thermoplastic component at Paris air show

Fibre2Fashion

time2 days ago

  • Business
  • Fibre2Fashion

Hexcel unveils breakthrough thermoplastic component at Paris air show

At Paris Air Show, Hexcel [NYSE: HXL] will spotlight its latest advancements in thermoplastic composite technology by showcasing a highly innovative PEKK/carbon thermoplastics component developed as part of the HELUES project. In 2018, Hexcel and Arkema have signed a strategic alliance to develop thermoplastic composite solutions for the aerospace sector combining the expertise of Hexcel in carbon fiber and that of Arkema in PEKK. At the Paris Air Show, the HELUES project perfectly illustrates thermoplastic solutions with a new demonstrator, a complex structural component for an overwing emergency exit door, and is the result of a multi-partner collaboration aimed at revolutionizing how aerospace components are manufactured for the next generation of high-rate aircraft production. Hexcel showcased a groundbreaking PEKK/carbon thermoplastics component at the Paris Air Show, developed under the HELUES project. This innovation enables high-rate, sustainable aerospace production by eliminating autoclaves and reducing assembly steps by up to 90 per cent. The one-step forming technology promises faster cycles, design flexibility, and recyclability for next-gen aircraft. 'The HELUES demonstrator is a milestone in aerospace thermoplastic composites,' said Thierry Merlot, Hexcel President Aerospace Europe, Asia Pacific, Middle East, Africa & Industrial . 'By eliminating autoclaves and enabling functional integration in a single step, thermoplastics are opening the door to truly scalable aircraft production.' As global demand surges for more efficient and scalable aircraft manufacturing, particularly for single-aisle jets, Hexcel and its HELUES partners are helping OEMs address critical production challenges through new material and process innovations. The HELUES project, funded by the Bavarian State Ministry of Economic Affairs and supported by the German Aerospace Centre, brought together Airbus Helicopters Deutschland GmbH, Neue Materialien Bayreuth GmbH, Siebenwurst GmbH & Co. KG, INCOE International Europe, ARKEMA and Hexcel to pioneer a new manufacturing process using high-temperature thermoplastics. At the core of the HELUES technology is a one-step forming and injection overmolding technology that utilizes HexPly unidirectional (UD) carbon fiber-reinforced Kepstan PEKK tapes in conjunction with Kepstan PEKK injection molding compounds. This integrated approach enables the rapid creation of a fully formed, structurally complex component, including reinforcing ribs and functional elements, in less than two minutes. Thermoplastics technology offers aerospace OEMs three key advantages: - Dramatically shortened cycle times - from hours to minutes - to meet production targets of up to 80-100 jets per month. - Greater design flexibility and weight savings, thanks to thermoplastics' ability to be reshaped and welded rather than fastened. - Enhanced sustainability and recyclability, as thermoplastics can be reprocessed and reused The HELUES demonstrator directly replaces a traditionally assembled door structure with a single, integrated part, reducing component count and assembly steps by up to 90%. Early-stage testing confirmed excellent material bonding between molded ribs and thermoformed laminates, even under complex process parameters, further supporting the part's viability in demanding aerospace environments. With the commercial aviation sector preparing for a future defined by high-rate production and more automated, sustainable assembly lines, thermoplastics are gaining momentum as a material of choice. By reducing reliance on energy-intensive autoclaves and enabling robotic manufacturing processes, solutions like the HELUES component demonstrate how composite innovation can unlock both performance and production scalability for the next generation of aircraft. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Fibre2Fashion News Desk (RM)

SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors
SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors

Yahoo

time12-06-2025

  • Business
  • Yahoo

SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors

New leadership and recapitalization to accelerate commercialization of proprietary silicon nitride technologies in medical and high-growth markets SALT LAKE CITY, Utah, June 12, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ('SINTX' or the 'Company'), the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, today announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of its intellectual property portfolio. This follows the company's successful recapitalization in February 2025 and the restructure of its leadership team and Board of Directors. A Legacy of Innovation in Silicon Nitride In 2008 SINTX Technologies made history with the first FDA-cleared implant material that is neither metal nor plastic—but medical-grade silicon nitride. The initial clearance covered a family of interbody devices and marked a pivotal moment in spinal surgery. These implants offered a unique trifecta of benefits: antimicrobial activity, osteogenic potential, and radiographic translucency. With over 50,000 spinal implants successfully placed worldwide, SINTX has demonstrated the clinical viability and long-term advantages of this revolutionary biomaterial. Today, SINTX remains the industry leader in silicon nitride technology, with 18 issued U.S. patents and 84 pending applications. Known for its strength, biocompatibility, and infection-resistant properties, the company's proprietary ceramic platform has applications across multiple markets—including the $62 billion global orthopedic implant sector, as well as emerging fields like agribiotech and performance textiles. Renewed Vision and Mission SINTX is now taking this one step further by developing next-generation hybrid biomaterials that combine the biological performance of silicon nitride and merging the flexibility, and manufacturability of polymers like PEEK and PEKK. These new composites are being optimized for applications in spine, oral/maxillofacial (OMF), cranio-maxillofacial (CMF), and oncologic reconstruction. 'Our mission is clear: to drive sustainable growth and value creation by collaborating with market leaders who recognize the transformative potential of silicon nitride,' said Mr. Eric Olson, CEO of SINTX Technologies. 'With a strengthened balance sheet and a robust intellectual property portfolio, we are uniquely positioned to accelerate commercialization and deliver superior outcomes for patients, customers, and shareholders alike.' Strategic Initiatives and Market Expansion SINTX is actively pursuing strategic partnerships and licensing opportunities to expand the reach of its technology. The company's near-term focus includes: Joint Ventures: Collaborating with established manufacturers in orthopedics, wound care, agribiotech, and other potential sectors to integrate silicon nitride into next-generation products. IP Monetization: Unlocking value from its extensive patent portfolio through licensing agreements and technology transfer initiatives. Operational Excellence: Enhancing AI supported 3D manufacturing capabilities at its FDA cleared and ISO certified headquarters to support anticipated growth and ensure the highest quality standards. Commitment to Stakeholders As SINTX enters this new era, the Company reaffirms its commitment to transparency, disciplined execution, and long-term value creation for all stakeholders. 'We are grateful for the continued support of our shareholders and partners,' said Mr. Olson. 'Together, we will realize the full potential of silicon nitride and secure SINTX's position as a leader in advanced ceramics. For more information, please visit About SINTX Technologies, Inc. Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ('PSLRA') that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,' "future," "likely," "may," "should," "will" and similar references to future periods. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Forward looking statements include our efforts to develop next-generation hybrid biomaterials, our expectation that will drive sustainable growth and value creation, and that we will expand the reach of our technology pursuing strategic partnerships and licensing opportunities. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in developing and commercializing medical device technologies. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law. Business and Media Inquiries for SINTX:SINTX Technologies, Inc. 801.839.3502IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store